INO vs MRNA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. INO and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined INO and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Inovio Pharmaceuticals is a clinical-stage biotechnology company built around a DNA medicines platform. The idea is to design small circular DNA molecules, called plasmids, that instruct a patient's own cells to produce specific proteins that target disease, and to deliver those plasmids using Inovio's proprietary CELLECTRA device rather than viral vectors or lipid nanoparticles. The company's most advanced program is INO-3107, an immunotherapy for recurrent respiratory papillomatosis (RRP), a rare condition in which HPV-driven benign tumors recur in the airway and often require repeated surgeries. Inovio's broader pipeline has historically centered on HPV-related diseases, including head and neck cancer (INO-3112) and cervical dysplasia (VGX-3100, whose US development was discontinued in 2023 while a partner pursues it in China).

Full INO guide

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• INO drivers: INO-3107 FDA decision for RRP; DNA medicines platform validation.
• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is binary clinical and regulatory outcome: the stock is tightly bound to the INO-3107 FDA decision, and rejection, a delay, or a request for more data could sharply reduce the company's value. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.

Pick INO if you believe its drivers more; MRNA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the INO and MRNA guides.

INO. Standard valuation multiples do not apply here: Inovio is pre-revenue and unprofitable, so metrics like P/E are meaningless and the equity is effectively an option on a small number of clinical and regulatory outcomes. Value is driven by the probability and timing of an INO-3107 approval, the cash runway, and dilution, not by earnings. Verify the latest cash position, share count, and program status before acting, as they can change quickly.

MRNA. MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

Headline figures (approximate, Jul 2026): INO shows revenue Effectively none; pre-revenue with no approved product on the market, profitability status Not profitable; sustained operating losses funded by capital raises, cash runway Management guided into roughly early 2027, near the target FDA decision, lead program stage INO-3107 (RRP) BLA under FDA review; target decision date around late Oct 2026; MRNA shows market cap ~$20 billion, q1 2026 revenue ~$400 million, q1 2026 net loss ~$1.3 billion (incl. ~$878M legal charge), 2026 revenue growth guidance up to ~10%.

INO and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined INO and MRNA exposure against your real portfolio. It is not an investment adviser.